Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4^-/- Mice

Area of Science:

• Endocrinology
• Hepatology
• Pharmacology

Background:

• The endocannabinoid system modulates inflammatory, fibrotic, metabolic, and carcinogenesis pathways via cannabinoid receptors (CB1 and CB2).
• Cholestasis, a condition of impaired bile flow, is associated with significant liver damage and metabolic dysfunction.

Purpose of the Study:

• To investigate the therapeutic potential of pharmacologic antagonism of the CB1 receptor in a mouse model of chronic cholestasis (Abcb4-/- mice).
• To evaluate the effects of CB1 receptor blockade on cholestasis-induced liver injury, inflammation, and associated signaling pathways.

Main Methods:

• Abcb4-/- mice were orally treated with rimonabant (a CB1 antagonist) or ACEA (a CB1 agonist) from weaning to 16 weeks of age.
• Liver tissue and serum were analyzed using biochemical assays, quantitative real-time PCR, Western blot, and immunohistochemistry.
• Untreated Abcb4-/- mice and wild-type mice served as controls.

Main Results:

• CB1 receptor antagonism with rimonabant significantly improved cholestasis-induced symptoms, including liver damage, bile duct proliferation, and elevated circulating bile acids.
• Rimonabant treatment normalized Phosphoenolpyruvate Carboxykinase expression, reduced inflammation, and mitigated the acute-phase response.
• CB1 antagonism suppressed the activation of carcinogenesis-associated signaling pathways, including JNK/c-JUN and STAT3, in Abcb4-/- mice.

Conclusions:

• Pharmacologic antagonism of the CB1 receptor demonstrates a protective effect in chronic cholestasis using the Abcb4-/- mouse model.
• Targeting the CB1 receptor may offer a therapeutic strategy for managing metabolic alterations, liver injury, inflammation, and carcinogenesis associated with cholestasis.